Forsythia fructus inhibits the mast-cell-mediated allergic inflammatory reactions

被引:48
作者
Kim, MS
Na, HJ
Han, SW
Jin, JS
Song, UY
Lee, EJ
Song, BK
Hong, SH
Kim, HM
机构
[1] Kyung Hee Univ, Coll Oriental Med, Dept Pharmacol, Seoul 130701, South Korea
[2] Wonkwang Univ, Coll Pharm, Dept Oriental Pharm, Iksan 571749, Jeonbuk, South Korea
[3] Wonkwang Univ, Coll Oriental Med, Iksan 570749, Jeonbuk, South Korea
关键词
Forsythia fructus; mast cells; oedema; histamine; tumor necrosis factor-alpha;
D O I
10.1023/A:1023865727780
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mast cells are key as effector cells in the early phase allergic inflammation and in diverse immunological and pathological processes. Forsythia fructus (F. fructus) has used as a traditional medicine for inflammatory diseases. In the present study, we determined the effect of F. fructus extracts on compound 48/80-induced paw oedema and vascular permeability in vivo. In addition, we investigated in vitro whether F. fructus has inhibitory effects on compound 48/80-induced histamine releases from rat peritoneal mast cells (RPMC), and on phorbol 12-myristate 13-acetate (PMA) plus A23187-induced tumor necrosis factor-alpha (TNF-alpha) releases from human mast cells (HMC-1). In mice orally administrered F. fructus (100 mug/g) for 1 h, compound-48/80-induced oedema and vascular permeability were significantly reduced rather than those receiving intravenous injection of ketotifen, mast cell stabilizer. F. fructus dose-dependently inhibited the histamine release induced by compound 48/80 from RPMCs. Moreover, F. fructus had no cytotoxic effects on cell viability and had inhibitory effects on TNF-alpha secretion from HMC-1. These results suggest that F. fructus is a potential herb medicine for treatment of inflammatory diseases through downmodulating mast cell activation.
引用
收藏
页码:129 / 135
页数:7
相关论文
共 43 条
[1]  
Assanasen Paraya, 2002, Clin Allergy Immunol, V17, P101
[2]   Immunopathology and human mast cell cytokines [J].
Bradding, P ;
Holgate, ST .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 31 (02) :119-133
[3]   COMPOUND-48/80 IS A POTENT INHIBITOR OF PHOSPHOLIPASE-C AND A DUAL MODULATOR OF PHOSPHOLIPASE-A2 FROM HUMAN-PLATELET [J].
BRONNER, C ;
WIGGINS, C ;
MONTE, D ;
MARKI, F ;
CAPRON, A ;
LANDRY, Y ;
FRANSON, RC .
BIOCHIMICA ET BIOPHYSICA ACTA, 1987, 920 (03) :301-305
[4]   NEURAL CONTROL OF VASCULAR-PERMEABILITY - INTERACTIONS BETWEEN PRIMARY AFFERENTS, MAST-CELLS, AND SYMPATHETIC EFFERENTS [J].
CODERRE, TJ ;
BASBAUM, AI ;
LEVINE, JD .
JOURNAL OF NEUROPHYSIOLOGY, 1989, 62 (01) :48-58
[5]   IDENTIFICATION OF MUTATIONS IN THE CODING SEQUENCE OF THE PROTOONCOGENE C-KIT IN A HUMAN MAST-CELL LEUKEMIA-CELL LINE CAUSING LIGAND-INDEPENDENT ACTIVATION OF C-KIT PRODUCT [J].
FURITSU, T ;
TSUJIMURA, T ;
TONO, T ;
IKEDA, H ;
KITAYAMA, H ;
KOSHIMIZU, U ;
SUGAHARA, H ;
BUTTERFIELD, JH ;
ASHMAN, LK ;
KANAYAMA, Y ;
MATSUZAWA, Y ;
KITAMURA, Y ;
KANAKURA, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (04) :1736-1744
[6]   Comparative morphofunctional study of dispersed mature canine cutaneous mast cells and BR cells, a poorly differentiated mast cell line from a dog subcutaneous mastocytoma [J].
Garcia, G ;
Brazis, P ;
Majo, N ;
Ferrer, L ;
de Mora, F ;
Puigdemont, A .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 1998, 62 (04) :323-337
[7]   KETOTIFEN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN ASTHMA AND ALLERGIC DISORDERS [J].
GRANT, SM ;
GOA, KL ;
FITTON, A ;
SORKIN, EM .
DRUGS, 1990, 40 (03) :412-448
[8]   Role of mast cell histamine in the formation of rat paw edema: A microdialysis study [J].
Guo, YC ;
Mochizuki, T ;
Morii, E ;
Kitamura, Y ;
Maeyama, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 331 (2-3) :237-243
[9]   Novel findings in inhibition of mast cell-dependent immediate-type cutaneous reactions by Gahmi-Shini-San [J].
Hong, SH ;
Kim, MS ;
Lee, JY ;
Hwang, CY ;
Baek, SH ;
Han, DS ;
Jung, WY ;
Seo, SB ;
Kajiuchi, T ;
Kim, HM .
CLINICA CHIMICA ACTA, 2001, 309 (01) :85-90
[10]   Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner [J].
Hultsch, T ;
Muller, KD ;
Meingassner, JG ;
Grassberger, M ;
Schopf, RE ;
Knop, J .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1998, 290 (09) :501-507